Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRZN vs CRBP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: SRZN 3 – 2 CRBP (1 Tie) Matrix Metrics: SRZN 5 – 2 CRBP

As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SRZN carries a Unified Composite Score of 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin), whereas CRBP carries 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. SRZN 34.3/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.3); meanwhile CRBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs CRBP
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.21β · 62% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 5.0 Fund 32.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 61
RSI-14: 61.3 · SMA20: $29.51 · SMA50: $26.10
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap $69.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.93β · 121% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.8%), weak momentum, RSI 34
RSI-14: 34.3 · SMA20: $3.83 · SMA50: $5.51

6-Pillar Scorecard Institutional Category Breakdown (SRZN 3 – 2 CRBP)

Columns: Metric · SRZN · CRBP
1. Valuation Multiples SRZN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 48.3x N/M
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% -100.0%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $602.5M $69.9M
3. Profitability & Quality CRBP
Gross Margin N/A N/A
Operating Margin -485.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -131.5%
4. Balance Sheet & Cash Flow CRBP
Cash Generation (TTM) -$31M -$92M
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 72.0% (5th %ile) 197.6% (66th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (5) vs CRBP (2)
Institutional Metric SRZN CRBP Criterion Row Edge
Market Capitalization
Scale
$602.5M $69.9M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% -100.0% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% 0.0% Higher Margin CRBP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -131.5% Higher ROE SRZN
52-Week Range Position
Momentum
79% ($12–$38) 6% ($3–$13) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.21β · 62% Vol 1.93β · 121% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 45.0 / 100 (HOLD) Higher Composite CRBP
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$92M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +63.21 pp
SRZN: +37.88% · CRBP: -25.33%
3M Horizon SRZN +101.19 pp
SRZN: +34.67% · CRBP: -66.52%
6M Horizon SRZN +83.86 pp
SRZN: +17.78% · CRBP: -66.08%
1Y Horizon SRZN +236.18 pp
SRZN: +166.67% · CRBP: -69.51%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue CRBP Revenue SRZN Op. Margin CRBP Op. Margin Margin Leader
FY2017 N/A $0M N/A -1334.4% CRBP
FY2018 N/A $0M N/A -1176.8% CRBP
FY2019 N/A $40M N/A -213.3% CRBP
FY2020 N/A $0M N/A -3119.2% CRBP
FY2021 N/A $0M N/A -6350.1% CRBP
FY2022 $10M N/A -354.7% N/A SRZN
FY2024 $10M N/A -239.7% N/A SRZN
FY2025 $0M N/A -1210.6% N/A SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRBP BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 197.6%
IV Percentile 66th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $69.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs CRBP Key Questions & Quantitative Answers

As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SRZN carries a Unified Composite Score of 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin), whereas CRBP carries 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. SRZN 34.3/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. -100.0% YoY). Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.3); meanwhile CRBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with CRBP at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), SRZN cumulative revenue shifted +0.0% while CRBP shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRBP.

SRZN screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas CRBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus CRBP (-131.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk). By comparison, CRBP carries 197.6% implied volatility (66th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.